India markets closed

Cipla Limited (CIPLA.BO)

BSE - BSE Real Time Price. Currency in INR
Add to watchlist
805.45-0.75 (-0.09%)
At close: 3:47PM IST
Full screen
Previous close806.20
Open806.20
Bid884.25 x 0
Ask885.00 x 0
Day's range800.75 - 811.75
52-week range356.75 - 878.55
Volume62,194
Avg. volume204,378
Market cap649.488B
Beta (5Y monthly)N/A
PE ratio (TTM)39.50
EPS (TTM)N/A
Earnings date06-Aug-2019 - 10-Aug-2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Indian pharma firms go local seeking to end reliance on China
    Reuters

    Indian pharma firms go local seeking to end reliance on China

    Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June. Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows. Executives at India's Cadila Healthcare, Cipla, Sun Pharmaceutical and ‎Biocon said on Tuesday they were aggressively working on reducing the dependence on the richer rival for raw materials.

  • Indian demand for COVID-19 drug remdesivir rising sharply - Cipla
    Reuters

    Indian demand for COVID-19 drug remdesivir rising sharply - Cipla

    Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness. Remdesivir was developed by U.S. drugmaker Gilead Sciences Inc <GILD.O>, which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.

  • Reuters

    Zydus Cadila launches India's cheapest remdesivir version at $37 per vial

    Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.